News From the Food and Drug Administration.

Citation metadata

Date: Mar. 16, 2021
Publisher: American Medical Association
Document Type: Article
Length: 52 words

Document controls

Main content

Abstract :

FDA approved lisocabtagene maraleucel (Breyanzi) as a chimeric antigen receptor T-cell therapy for large B-cell lymphoma. It authorized eXciteOSA, a device that uses electrical stimulation to help alleviate snoring and mild obstructive sleep apnea. Moreover, the agency is developing guidance for medical equipment manufacturers to aid their response to emerging SARS-CoV-2 variants.

Source Citation

Source Citation   

Gale Document Number: GALE|A666938880